To characterize the stone risk and the impact of parathyroidectomy on the metabolic profile of patients with primary hyperparathyroidism (PHPT) and urolithiasis.
Introduction
The prevalence of kidney stones varies from 7% to 12% [1, 2] . Particular metabolic risk factors play a key role in the formation of renal stones, notably hypercalciuria, low urinary volume, low concentration of inhibitors such as citrate, and high consumption of calories, sodium and proteins. Hypercalciuria is one of the hallmarks of primary hyperparathyroidism (PHPT) [3] . PHPT is a disease of mineral metabolism characterized by excessive secretion of parathyroid hormone (PTH) produced by one or more parathyroid glands [4] . It effects one in every 500 women and one in every 2 000 men aged >40 years, with a peak incidence in postmenopausal women between the ages of 50 and 60 years [5] [6] [7] . Although it may be related to genetic syndromes, the sporadic form of PHPT is predominant.
In recent series, 7% to 18% of patients with PHPT had kidney stones. By contrast, only 2% to 8% of patients with urolithiasis have PHPT [8, 9] . Currently, most patients with PHPT are asymptomatic and have hypercalcaemia detected in routine serum evaluation [10] . The classic clinical manifestations of PHPT arise from the chronic and persistent elevation of serum calcium and PTH level, with nephrolithiasis and bone dysfunctions being the most common conditions in this setting [10, 11] . Individuals with vitamin D deficiency and PHPT present with a clinically more exuberant bone and kidney disease [10] [11] [12] [13] .
The pathophysiology of urinary tract lithiasis in patients with PHPT and the factors that would indicate a greater risk of renal calculi formation have not yet been elucidated. Most patients with PHPT do not develop urolithiasis and some studies have correlated the prevalence of nephrolithiasis with the intensity of hypercalciuria in these patients [14, 15] , although no concrete association has been found between the disease and serum and urinary calcium levels [16] [17] [18] . Patients with symptomatic PHPT are candidates for parathyroid gland removal, and parathyroidectomy is an effective therapy in curing the primary disease, in addition to decreasing the risk of nephrolithiasis in the long term [18, 19] . Parathyroidectomy also helps to increase bone mineral density and improve the quality of life of patients with PHPT. The increased incidence of stone recurrence after surgery, however, indicates that this intervention alone may not be enough for a subset of patients with PHPT [18, 19] .
The aim of the present study was to characterize the stone risk and to evaluate the impact of parathyroidectomy on the metabolic profile of patients with confirmed PHPT and urolithiasis.
Patients and Methods
After institutional review board approval, the prospectively collected charts of all patients from the Urology Clinic of our institution with renal calculi diagnosed with PHPT between January 2001 and January 2016 were reviewed. Patients with secondary causes of hyperparathyroidism, e.g. gastrointestinal disorders, renal insufficiency, vitamin D insufficiency, diminished calcium intake, and hypercalciuria of renal origin were excluded. Also, patients with multiple endocrine neoplasia type 1 (MEN1) and type 2 (MEN2) were not considered in the final analysis, and only sporadic cases of PHPT were included.
The demographic profile of all patients was collected, including gender, age, ethnicity, body mass index (BMI), and date of the first consultation at our clinic. Complete serum and urinary metabolic evaluation was completed before and after parathyroidectomy. Serum levels of total calcium, ionic calcium, phosphate, PTH, creatinine, urea, sodium, potassium, uric acid, and 25-hydroxy-vitamin D were noted. For 24-h urine analysis, urinary volume, calcium, creatinine, oxalate, citrate, sodium, uric acid, potassium, and magnesium were verified. In a single collection urine analysis, the fasting urinary pH was evaluated (normal range 5.8-6.2). Before and after parathyroidectomy, we considered for metabolic evaluation the 24-h urinary collection closest to the procedure. Patients receiving medical therapy with thiazides, citrate or allopurinol were excluded from the analysis. Patients receiving calcium and vitamin D supplementation were maintained in the study.
Kidney stones were evaluated by ultrasonography and/or CT of abdomen and pelvis. Parathyroid scintigraphy and ultrasonography were performed to identify anatomical aspects of the gland. The bone densitometry test, when available, was also assessed. The history of clinical signs and symptoms related to the stone disease and PHPT were attained.
Before parathyroidectomy, the urinary and serum analyses and PTH levels of patients with PHPT were appraised. A correlation analysis was performed between those parameters and also between the same factors and the imaging tests, to determine the presence of an association between the severity of the metabolic disorder, urolithiasis burden, and the findings of the parathyroid imaging evaluation. All the other metabolic disorders predisposing to renal calculi were evaluated. In the peri-operative period of the parathyroidectomy, type of surgery, success rate and the impact on metabolic risk were assessed. 
Results

Study Population and Demographic Data
After initial screening of all patients with suspicion of PHPT and renal stones, the cases were analysed one by one to ascertain the definitive diagnosis of sporadic PHPT. Of the 61 patients initially selected, 10 were excluded: six had MEN1 or MEN2, three had no confirmed diagnosis of PHPT after complete metabolic and imaging evaluation, and one patient had a history of back pain without confirmation of renal stones on CT. Our final study population consisted of 51 patients with urinary lithiasis and sporadic PHPT.
Of the 51 patients analysed, 42 (82.4%) were women, with a men:women proportion of 1:4.7. Most patients were white (n = 42; 82.4%) and their mean AE SD (range) age was 57.1 AE 
Stone Disease Presentation and Severity
The majority of the patients (n = 37; 72.5%) had a diagnosis of stone disease prior to PHPT. In the diagnostic investigation, PHPT was identified at a mean of 20.2 AE 49.5 (range À1 685.9 to 144.7) months after the urinary calculi. Patients were referred from the Endourology Department to the Head and Neck or Endocrinology Centre in most cases, with the reverse occurring 27.5% of the time.
At the time of stone disease diagnosis, 70.6% (n = 36) were symptomatic, almost all presenting renal colic. Eleven (21.6%) patients had low stone burden and were managed with dietary changes and close follow-up. Among the 40 remaining, 10 (19.6%) required only one intervention, 13 (25.5%) two, and 17 (33.3%) three or more surgical procedures. The mean number of procedures per patient was 1.7 AE 1.3, ranging from 0 to 4.
The first surgical intervention consisted of extracorporeal shockwave lithotripsy in 11 patients (21.6%), endoscopic ureterolithotripsy in 14 (27.5%), percutaneous nephrolithotripsy in 13 (25.5%) and total nephrectomy in two (3.9%). Taking into account the entire follow-up period, three more patients required total nephrectomy. In 25 patients (48.1%), urinary stone analysis data were not available. Of the 26 remaining patients, 10 (38.5%) had pure calcium oxalate stone, nine (34.6%) had phosphate and calcium oxalate calculi, and seven (29.9%) had struvite stones. The individualized urinary pH analysis of patients with calcium oxalate, phosphate and struvite stones revealed 5.61 AE 0.60, 5.94 AE 0.77 and 6.0 AE 0.55, respectively, although no significant difference between groups was found (P = 0.449).
Metabolic Risk in Patients with Primary Hyperparathyroidism
Before parathyroidectomy, mean total and ionic calcium levels were 11.2 AE 1.0 mg/dL and 6.2 AE 0.7 mg/dL, respectively. Hypercalcaemia was present in 43 individuals (84.3%) and the lowest serum calcium found was 9.7 mg/dL. Of the eight patients with normocalcaemic hyperparathyroidism, all had elevated serum PTH levels and five (62.5%) had hypercalciuria. Two of the eight normocalcaemic patients had low phosphate levels (2.1 and 2.6 mg/dL) and six had normal levels, although three of these were in the lower range (2.7 mg/dL). In addition, all had normal creatinine levels, three had elevated ionized calcium, five had vitamin D levels between 20 and 30 ng/mL and three had vitamin D levels <20 ng/mL. The mean preoperative PTH level was 331 AE 584 pg/dL, ranging from 33 to 3 567. Only two patients did not have PTH above the normal range, although both had elevated total calcium levels: 10.3 and 10.9 mg/dL. Hypophosphataemia and hyperuricaemia were found in 43.1% and 29.4%, respectively. Table 1 shows the prevalence of serum and urinary metabolic disorders in the studied population before and after parathyroidectomy. Absolute values of the same metabolic variables are shown in Table 2 .
The number of urinary metabolic disturbances in each individual ranged from 0 to 5 before parathyroidectomy and only two patients (3.9%) did not present with any urinary disorder. Overall, 39.2% (n = 20) of cases had at least two abnormalities and 35.3% (n = 18) had three (n = 14), four (n = 3) or five (n = 1) disorders. The most common urinary disorders were low urinary volume (64.7%), followed by hypercalciuria (60.8%), high urinary pH (41.2%) and hypocitraturia (31.4%) ( Table 1 ). The mean preoperative calciuria level was 269.1 AE 145.4 mg/vol.24 h, ranging from 28.8 to 634.7 ( Table 2 ). Out of the 51 patients, 11 (21.6%) had urinary calcium levels between 200 and 300 mg/vol.24 h, 12 (23.5%) between 300 and 400, five (9.8%) between 400 and 500, and three (5.9%) >500 mg/vol.24 h.
The correlation between the mean values of total calcium, ionic calcium, PTH, vitamin D, and urinary calcium before parathyroidectomy were studied. Total serum calcium did not significantly correlate with PTH (R = À0.069; P = 0.63), vitamin D (R = À0.099; P = 0.51), or urinary calcium (R = 0.086; P = 0.56). Serum ionic calcium also did not significantly correlate with PTH (R = À0.187; P = 0.19), vitamin D (R = À0.259; P = 0.08), or urinary calcium (R = 0.215; P = 0.15). Vitamin D had a nonsignificant correlation with PTH (R = À0.153; P = 0.31) and urinary calcium (R = À173; P = 0.25). The only significant association was found between serum PTH and urinary calcium (R = À0.304; P = 0.04): the higher the PTH value, the lower the urinary calcium value and vice versa ( Fig. 1) .
Primary Hyperparathyroidism Imaging Diagnosis and Parathyroidectomy Efficacy
Parathyroid scintigraphy was available for analysis in 49 of 51 cases. In five patients (9.8%), scintigraphy was inconclusive and in four of these patients, ultrasonography did not show a parathyroid nodule. Nevertheless, PTH was markedly elevated and intra-operative pathology confirmed parathyroid hyperplasia of the suspected enlarged parathyroid gland during neck exploration. In the remaining 44 cases with positive scintigraphy findings, the presence of one or two hyperfunctioning glands was found in 42 (82.4%) and two (3.9%) cases, respectively. Two patients (3.9%) had ectopic parathyroid glands on preoperative scintigraphy, both being close to the sternal furcula.
Of the 51 patients, 13 (25.5%) had no bone densitometry data. Of those who had bone densitometry (n = 38), eight (21.1%) had normal examinations, 20 (52.6%) had osteopenia, and 10 (26.3%) had osteoporosis. No significant correlations were found between total calcium, PTH, vitamin D, and urinary calcium levels with the number of hyperfunctioning parathyroid glands, ectopic adenoma and bone densitometry (P = non-significant). Parathyroidectomy was successfully performed in all cases, averaging 13.3 AE 21.4 (0.4-72.1) months after PHPT diagnosis. With a mean (range) follow-up of 71.2 AE 41.3 (18.9-180.9) months, no patient required a new approach because of an eventual relapse of the disease.
Impact of Parathyroidectomy on Metabolic Variables
Metabolic evaluation was performed 3.6 AE 3.5 months after parathyroidectomy (median 2.2 months). In the postoperative period, the number of patients with hypercalcaemia (n = 4; 7.8%), elevated PTH (n = 17; 33.3%) and hypophosphataemia (n = 3; 5.9%) significantly decreased (P < 0.001; Table 1) . Absolute values of total calcium, ionic calcium and PTH showed a significant reduction (P < 0.01; Table 2 ), with a mean reduction in total serum calcium and PTH levels of 1.78 AE 1.19 mg/dL and 296.7 AE 596.5 pg/mL, respectively. Conversely, mean vitamin D levels increased from 19.7 to 27.6 ng/mL and phosphorus levels from 2.6 to 3.3 mg/dL (P < 0.001). Calciuria presented a mean reduction of 106.6 AE 152.3 mg/vol.24 h (P < 0.001). No patient with persistent calcium or PTH levels had disease recurrence on imaging and clinical evaluation.
The number of urinary abnormalities after parathyroidectomy ranged from 0 to 5. Four patients (7.8%) had no alterations and most of the individuals had only one disorder (31.4%); 17.6% had at least two abnormalities, and 23.5% had three or more disorders. In relation to the preoperative period, there was a reduction in the number of patients with hypercalciuria (n = 7, 13.7%; P < 0.001) and elevated pH (n = 10, 19.6%; P = 0.021). When analysing the absolute mean values, a reduction in urinary calcium levels (P < 0.001), pH (P = 0.001) and citrate (P = 0.003) was observed compared with preoperative levels (Table 2) .
Discussion
The present study shows that parathyroidectomy in individuals with sporadic PHPT leads to marked changes in the metabolic stone risk profile, yet almost all patients have residual abnormalities that warrant close follow-up and preventive measures. To avoid contamination in data analysis, we considered only the sporadic form of the disease, excluding cases of MEN1 and MEN2 syndrome, which corresponded to 9.8% of our initial sample. Previous studies have shown that between 80% and 95% of PHPT cases are sporadic [20] [21] [22] , corroborating our findings. The men:women ratio of our study was 1:4.7, similar to that of previous studies [5] [6] [7] 16] . Elkoushy et al. [17] analysed patients with PHPT before parathyroidectomy and found that individuals with no history of nephrolithiasis were significantly older than those with nephrolithiasis (61.3 vs 56.4 years, respectively; P = 0.02). Our cohort included only patients with nephrolithiasis and their mean age was 57 years, similar to that of previous series [16, 17, 23, 24 ].
An important aspect of the present study was the mapping of serum calcium and PTH levels in individuals with PHPT and renal lithiasis. In this series, elevated PTH level had 96.1% sensitivity for detection of PHPT; however, the sensitivity of total serum calcium was lower, at 84.3%, and all individuals with normal calcium had elevated PTH levels. Considering that the algorithms for the investigation of metabolic causes of nephrolithiasis only propose the collection of serum PTH when a high total calcium value is present [25] , our data raise some concern as we may be failing to make an accurate diagnosis of PHPT in up to 15.7% of our patients; therefore, one could propose two alternatives: we could collect serum PTH in all individuals with recurrent nephrolithiasis at the same time as calcium collection or we could lower our suspicion threshold to a total serum calcium level of 9.7 instead of 10.2 mg/dL, because this was the lowest value found in our sample. The first hypothesis would identify more patients with PHPT, although it would have a higher cost in the screening of the population with nephrolithiasis.
Considering that more severe and relapsing cases of nephrolithiasis are referred to tertiary centres, the routine testing for PTH in such patients is already established at our institution as this selected group did not represent a significant expense. Nonetheless, the main message is to maintain high suspicion to avoid misdiagnosing PHPT cases. We had eight patients with normocalcaemic hyperparathyroidism, although most had mild vitamin D deficiency. The evaluation of this specific cohort will be reason for a subsequent investigation.
Hypercalciuria was present in only approximately half our sample, with a mean urinary calcium level of 261 mg/ vol.24 h. Extreme hypercalciuria, calcium level >400 mg/ vol.24 h, was only found in 15% of patients. Hence, identification of individuals with PHPT based on the severity of calciuria alone is not effective. Elkoushy et al. [23] found hypercalciuria in 52.1% of patients with PHPT. In the study by Sorensen et al. [24] , hypercalciuria was identified in 68% of patients with PHPT and history of nephrolithiasis and in 62% of patients with PTH without a history of urinary calculi. In the present series,~40% of the individuals had normal urinary calcium levels but all had nephrolithiasis; therefore, hypercalciuria is not an isolated factor for stone formation in patients with PHPT.
The present study was the first to evaluate systematically the prevalence of non-calcium metabolic disorders that predispose to the formation of renal calculi in individuals with PHPT before and after parathyroidectomy. Although the classic mechanism described is that of hypercalciuria, we found that most of our patients had other metabolic disorders in their initial analysis, with the most common being low urinary volume, elevated pH and hypocitraturia. Urinary pH is high, probably as a result of increased PTH, which inhibits renal tubular reabsorption of filtered phosphate. Consequently, phosphaturia and mild hyperchloraemic acidosis may develop and contribute to hypocitraturia. The mean citrate level prior to parathyroidectomy was 425 mg/vol.24 h, below that reported in previous series [17, 23, 24] . Lithogenic factors other than hypercalciuria that are associated with PHTP may vary according to the population and geographic region studied. Thus, complete metabolic evaluation is advised in patients with PHPT and nephrolithiasis in contrast to an analysis focused on calcium metabolism. Considering that the metabolic profile of patients with PHPT with and without nephrolithiasis is similar [17, 23, 24] , we can extrapolate this recommendation to all patients with PHPT. Just recently, in a Canadian and international consensus paper, it was stated that although there are no consistent data available on the role of performing metabolic evaluation of stone formers with PHPT, because of the persistent increased risk after surgical cure of the disease, it is reasonable to consider screening for other frequent risk factors for kidney stone disease [26] . Metabolic syndrome and obesity have been associated with stone disease [3, 7] . We did not find a significant association between BMI, urinary pH and stone disease severity in our cohort of patients with PHPT.
The impact of parathyroidectomy on metabolic risk related to calcium metabolism was similar to that previously described. There is a reduction in serum calcium, PTH and calciuria, while vitamin D and serum phosphorus levels rise [16] [17] [18] 23, 24] ; however, the prevalence of other metabolic disorders before and after parathyroidectomy is unique to the present study. In addition to the typical PHPT changes with hypercalcaemia, hypophosphataemia and hypercalciuria, we observed a high prevalence of patients with low urinary volume, hypocitraturia and hypernatriuria before and after parathyroidectomy. After surgery, more than half of the patients had low urinary volume and one-third had hypercalciuria, even with dietary recommendations for the prevention of nephrolithiasis. Despite the concomitant decrease in urinary pH, almost 20% of the studied population still had urinary pH above normal values and 15% maintained hypernatriuria. Moreover, one third of patients still had hypocitraturia and mean urinary level of citrate significantly decreased to 261 mg/vol.24 h. The mechanism is unclear, although citrate levels in the urine are reduced in acidotic states, as well as when levels of PTH and vitamin D are decreased. This finding helps us to understand the true metabolic risk of patients with nephrolithiasis and PHPT. Also, it might explain why the risk of stone formation does not decrease immediately after the correction of hypercalcaemia and hypercalciuria with parathyroidectomy [18, 19] . Monitoring of these metabolic abnormalities is mandatory, and citrate reposition with oral potassium citrate may play an even more important role. Importantly, twothirds of our cohort had struvite or phosphate stones, which are associated with high urinary pH, as previously described [27] ; therefore, citrate supplementation should take place under close examinination of urinary pH.
Unlike previous series [16, 23] , parathyroidectomy was effective in 100% of the cases. This was because the two patients with ectopic hyperfunctioning parathyroid glands were identified on initial scintigraphy and treated appropriately. Berger et al. [16] reported failure in three of 54 cases, with a disease recurrence rate of 5.5%. In all cases, the parathyroid was in an ectopic position and was successfully removed in a second intervention. In our experience within a tertiary centre, the intimate communication between urology and head and neck surgery and endocrinology departments is essential so that patients with PHPT and urinary tract lithiasis are treated appropriately. There are no guidelines with regard to which treatment should take place first, although patients with an obstructing ureteric stone would probably benefit from ureteroscopy prior to parathyroidectomy. Individuals with asymptomatic kidney stones should have their parathyroid gland removed as the initial therapy. Concurrent procedures are feasible but not advised. A large amount of equipment (e.g. video tower and C-arm) is necessary for the urological approach and the pathological parathyroid gland may be challenging to find during neck exploration, increasing the operating time.
In theory, patients with vitamin D deficiency and PHPT have a clinically more exuberant spectrum of disease, with highervolume parathyroid adenomas, higher serum PTH levels, more rapid bone metabolism, and a higher incidence of fractures [12, 13] . The serum vitamin D level before parathyroidectomy of our population was 19.7 ng/mL, similar to that of previous series. It has been proposed that the serum level of 1,25-dihydroxyvitamin D would influence the propensity to form nephrolithiasis [28] . Elkoushy et al. [23] showed that individuals with PHPT and nephrolithiasis had lower serum vitamin D levels (19.7 ng/mL) than those with no stones (22.8 ng/mL). Recent studies have shown that patients with PHPT and low levels of vitamin D exhibit increased bone catabolism with consequent lower bone density [29, 30] . Another study showed that restrictive diets in calcium are detrimental to patients with PHPT [31] . Taken together, these results suggest that higher serum levels of vitamin D in patients with PHPT without nephrolithiasis might protect these patients from the bone reabsortive effects caused by PTH. In addition, they may increase the intestinal absorption of calcium and phosphate and decrease the renal excretion of the same compounds, thus reducing the risk of kidney stones [32] . Despite this, this effect does not appear to translate into a lower clinical calciuria, as the urinary calcium levels of individuals with PHPT and nephrolithiasis are similar to those without nephrolithiasis in all the studies [16, 17, 23, 24] . In the present series, the vitamin D level did not influence calciuria and did not reflect the degree of bone involvement determined by bone densitometry. The impact of vitamin D repletion on urinary metabolic risk was not appraised in the present study.
This study corroborates the understanding that a high index of suspicion is necessary for the identification and adequate
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© 2017 The Authors BJU International © 2017 BJU International treatment of patients with renal lithiasis and PHPT. Complete serum and urinary metabolic assessment is indispensable for the recognition of all potential lithogenic factors in individuals with PHPT. Treatment with parathyroidectomy should be carried out rapidly and is effective in improving the body metabolism of calcium, reducing potential damage to the kidneys and bone; however, it does not culminate with normalization of all urinary variables, which should be delineated and treated in a particularized manner. Oral citrate supplementation might be especially important in this cohort of patients. Prospective clinical studies and genetic risk evaluation constitute the next step to improve patient management. Ongoing coordinated follow-up by urology and endocrinology is warranted. Drawbacks of the investigation are the retrospective nature, the limited number of patients, and the lack of long-term follow-up to determine the impact of surgery on the metabolic risk and stone recurrence.
Individuals with PHPT and nephrolithiasis present elevated baseline PTH levels in almost all cases, with serum calcium being increased in most individuals. In patients with serum calcium within the upper limit and hypercalciuria, PTH assessment improves the accuracy of PHPT diagnosis. Low urinary volume, hypercalciuria, high urinary pH, and hypocitraturia are the most frequent urinary disorders in this population. Treatment with parathyroidectomy is effective in normalizing serum calcium and PTH levels, in addition to increasing vitamin D, but it does not lead to a similar degree of resolution of hypercalciuria. The frequency of urinary metabolic disorders after parathyroidectomy is high and should be routinely investigated in patients with PHPT and nephrolithiasis.
